SOUTHLAKE, Texas--(BUSINESS WIRE)--OncoNano Medicine, Inc. (“OncoNano”), a clinical-stage biotechnology company ... will present a Trials in Progress poster at the upcoming 2024 American ...

Krystal Biotech, Inc. announced that it will present ... Presentation slides or posters will be available online in the Investor section of the Company's website after each conference.

DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) unveiled significant findings from its Phase 3 IMPALA-2 clinical trial of ...

MAIA Biotechnology, Inc., (NYSE American ... a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking ...

Substantial technical and intellectual skills will be developed in areas such as stem cells, gene therapy, regenerative medicine ... and outside of Northwestern. Annual Biotechnology, Systems, and ...

The second abstract accepted for poster presentation contains new pre-clinical data for the next candidate in the IO Biotech pipeline, IO112, which targets Arginase 1. Times: Poster hall ...

(“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer cell therapeutics, today ...

Cambridge, MA – March 5, 2025 – Today, Insilico Medicine, a clinical-stage biotechnology company pioneering generative AI for drug discovery and development, announced the deployment of the ...

Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC) MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a ...